This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
Speaking at recent investor conferences, Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.
“It’s one of the three scientific areas that are our core focus,” Gilead Chief Financial Officer Andy Dickinson told investors at the Cantor Global Healthcare Conference earlier this month. “We’re the largest virology company. We’ve built a robust oncology business. The third leg of the stool, so to speak, is the I&I [inflammation and immunology] business that we’re growing.”
